Suppr超能文献

精准医学与心血管预防及人群健康:难以跨越的桥梁?

Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far?

机构信息

Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX (F.R.G., J.D.B., A.K., A.M.S., J.A.d.L.).

Department of Medicine, University of Texas at Tyler (J.D.B.).

出版信息

Circulation. 2024 Nov 19;150(21):1720-1731. doi: 10.1161/CIRCULATIONAHA.124.070081. Epub 2024 Nov 18.

Abstract

Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available. However, progress has been modest to date with few precision tools available for clinicians. Arguably, cardiovascular prevention and population health are poised for innovation to guide evaluation and management, as these areas are already informed by risk-assessment, but limited by the use of crude assessment tools with marginal performance. Risk assessment in prevention and population health may be improved with the use of genetics, circulating biomarkers, and imaging, leading to outcome-specific risk-prediction and enhanced phenotyping. Personalized management matching therapy to risk profile can be then implemented for either individuals or groups, improving cost-effectiveness and risk-benefit. Here, we explore this precision-like approach, including available tools, potential applications, and future perspectives for cardiovascular prevention and population health management.

摘要

精准医学旨在提供基于反映潜在病理生理学的工具的个性化临床护理。鉴于有大量可用的指南指导的医学治疗方法,心血管医学对这种方法的需求从未如此之大。然而,迄今为止进展甚微,可供临床医生使用的精准工具寥寥无几。可以说,心血管预防和人群健康正处于创新的边缘,以指导评估和管理,因为这些领域已经通过风险评估来指导,但受到使用粗糙评估工具的限制,这些工具的性能有限。通过使用遗传学、循环生物标志物和影像学,可以改善预防和人群健康中的风险评估,从而进行特定于结果的风险预测和增强表型分析。然后可以为个人或群体实施匹配风险概况的个性化管理,提高成本效益和风险效益。在这里,我们探讨这种类似精准的方法,包括可用的工具、潜在的应用以及心血管预防和人群健康管理的未来展望。

相似文献

1
Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far?
Circulation. 2024 Nov 19;150(21):1720-1731. doi: 10.1161/CIRCULATIONAHA.124.070081. Epub 2024 Nov 18.
2
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
Precision medicine for suicidality: from universality to subtypes and personalization.
Mol Psychiatry. 2017 Sep;22(9):1250-1273. doi: 10.1038/mp.2017.128. Epub 2017 Aug 15.
6
Cases in Precision Medicine: A Personalized Approach to Stroke and Cardiovascular Risk Assessment in Women.
Ann Intern Med. 2019 Dec 3;171(11):837-842. doi: 10.7326/M19-1601. Epub 2019 Oct 15.
7
Why Does the Shift from "Personalized Medicine" to "Precision Health" and "Wellness Genomics" Matter?
AMA J Ethics. 2018 Sep 1;20(9):E881-890. doi: 10.1001/amajethics.2018.881.
9
Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine.
Expert Rev Cardiovasc Ther. 2017 Jul;15(7):547-558. doi: 10.1080/14779072.2017.1348228. Epub 2017 Jul 6.
10

引用本文的文献

1
Cardiovascular and Metabolic Disease: New Treatment and Future Directions-The 3rd Edition.
Biomedicines. 2025 Aug 6;13(8):1914. doi: 10.3390/biomedicines13081914.
2
The Big Data Era in Cardiology and Cardiovascular Medicine: Advanced Analytics for Truly Personalized Care.
Diagnostics (Basel). 2025 Jul 3;15(13):1705. doi: 10.3390/diagnostics15131705.

本文引用的文献

1
Prognostic Value of Cardiovascular Biomarkers in the Population.
JAMA. 2024 Jun 11;331(22):1898-1909. doi: 10.1001/jama.2024.5596.
2
Large-Scale Proteomics Identifies Novel Biomarkers and Circulating Risk Factors for Aortic Stenosis.
J Am Coll Cardiol. 2024 Feb 6;83(5):577-591. doi: 10.1016/j.jacc.2023.11.021.
4
Towards personalized medicine for cystic fibrosis patients with rare mutations.
J Physiol. 2024 Jan;602(2):257-258. doi: 10.1113/JP286135. Epub 2024 Jan 3.
7
Development and Validation of the American Heart Association's PREVENT Equations.
Circulation. 2024 Feb 6;149(6):430-449. doi: 10.1161/CIRCULATIONAHA.123.067626. Epub 2023 Nov 10.
8
Mendelian Randomization as a Tool for Cardiovascular Research: A Review.
JAMA Cardiol. 2024 Jan 1;9(1):79-89. doi: 10.1001/jamacardio.2023.4115.
9
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association.
Circulation. 2023 Nov 14;148(20):1606-1635. doi: 10.1161/CIR.0000000000001184. Epub 2023 Oct 9.
10
Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America.
J Card Fail. 2023 Oct;29(10):1412-1451. doi: 10.1016/j.cardfail.2023.07.006. Epub 2023 Sep 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验